¼¼°èÀÇ ¼Ò Ç÷Àå À¯µµÃ¼ ½ÃÀå
Bovine Blood Plasma Derivatives
»óǰÄÚµå : 1797198
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 289 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¼Ò Ç÷Àå À¯µµÃ¼ ½ÃÀåÀº 2030³â±îÁö 24¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 19¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¼Ò Ç÷Àå À¯µµÃ¼ ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 3.9%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 24¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¸é¿ª±Û·ÎºÒ¸° À¯µµÃ¼´Â CAGR 3.2%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6¾ï 7,170¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇǺ긮³ë°Õ À¯µµÃ¼ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 5.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5¾ï 1,510¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ¼Ò Ç÷Àå À¯µµÃ¼ ½ÃÀåÀº 2024³â¿¡´Â 5¾ï 1,510¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£2024-2030³â CAGRÀ» 7.1%·Î, 2030³â±îÁö 4¾ï 7,920¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.7%¿Í 3.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¼Ò Ç÷Àå À¯µµÃ¼ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¼Ò Ç÷Àå À¯µµÃ¼°¡ ¹ÙÀÌ¿À ÀÇ·á ¹× µ¿¹° ¿µ¾ç »ê¾÷¿¡ Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¼Ò Ç÷Àå À¯µµÃ¼´Â ƯÈ÷ »ý¹° ÀÇÇÐ ¿¬±¸, ÀǾàǰ Á¦Á¶, µ¿¹° ¿µ¾çÇÐ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ ÇʼöÀûÀÎ ¼ººÐÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¼Ò Ç÷¾×ÀÇ Ç÷Àå ºÐȹ¿¡¼­ ¾òÀº À̵é À¯µµÃ¼¿¡´Â ¾ËºÎ¹Î, ¸é¿ª±Û·ÎºÒ¸°, ÇǺ긮³ë°Õ, ¼ºÀåÀÎÀÚ µî ±â´É¼º ´Ü¹éÁúÀÌ Ç³ºÎÇÏ°Ô ÇÔÀ¯µÇ¾î ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸ÞµðÄà ºÐ¾ß¿¡¼­´Â ¹èÁö ÷°¡Á¦, ¹é½Å ¾ÈÁ¤È­Á¦, ¾àÁ¦Á¦Á¦ÀÇ Ä³¸®¾î·Î ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Àΰ£°ú µ¿¹°ÀÇ ¼¼Æ÷°è¿¡ ÀûÇÕÇÏ¿© Á¶Á÷°øÇÐ, Áø´ÜÇÐ, ¹ÙÀÌ¿ÀÀǾàǰ °³¹ß¿¡ ÀÌ»óÀûÀÔ´Ï´Ù. µ¿¹° ¿µ¾ç »ê¾÷¿¡¼­ ¼Ò Ç÷Àå ´Ü¹éÁúÀº °íǰÁú »ç·á÷°¡Á¦, ƯÈ÷ ÀÚµ·°ú ¼Û¾ÆÁö »ç·á¿¡ »ç¿ëµÇ¾î ¼ºÀå ÃʱâÀÇ ¸é¿ª Áö¿ø°ú Àå³» ȯ°æ °³¼±¿¡ µµ¿òÀÌ µË´Ï´Ù. ¼Ò Ç÷ÀåÀ» »ç·á¿¡ »ç¿ëÇÏ¸é ¼ºÀ强ÀûÀÌ Çâ»óµÉ »Ó¸¸ ¾Æ´Ï¶ó Ç×»ýÁ¦ »ç¿ë·®À» ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, Ç×»ýÁ¦¸¦ »ç¿ëÇÏÁö ¾Ê´Â Ãà»êÀ» ÁöÇâÇÏ´Â ¼¼°èÀûÀÎ ¿òÁ÷ÀÓ°ú ÀÏÄ¡ÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ À¯µµÃ¼´Â ¾ö°ÝÇÑ ¾ÈÀü ÇÁ·ÎÅäÄÝ¿¡ µû¶ó °¡°øµÇ¹Ç·Î º´¿ø±ÕÀÇ À§ÇèÀÌ ³·°í »ý¹°ÇÐÀû Ȱ¼ºÀÌ ¾ÈÁ¤ÀûÀÔ´Ï´Ù. Áö¼Ó°¡´ÉÇÑ °ø±Þ¿øÀ¸·ÎºÎÅÍÀÇ ±â´É¼º ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä´Â ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¼Ò Ç÷Àå À¯µµÃ¼´Â À°·ù °¡°øÀÇ Á¦Ç°º°·Î Ȱ¿ëµÇ´Â ¼Ò Ç÷Àå À¯µµÃ¼´Â ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¼Ò Ç÷Àå À¯µµÃ¼´Â À°·ù °¡°øÀÇ Á¦Ç°º° Á¦Ç°À» ÀÌ¿ëÇÏ¿© ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. Àü ¼¼°è Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó »ý¹°ÀǾàǰ°ú µ¿¹°¼º ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼Ò Ç÷Àå À¯µµÃ¼´Â °Ç°­ ¼º°ú¿Í ¿µ¾ç ¼º´ÉÀ» Çâ»ó½Ã۱â À§ÇØ °¢ ºÐ¾ß¿¡¼­ Áß¿äÇϰí È®´ëµÈ ¿ªÇÒÀ» °è¼ÓÇϰí ÀÖ½À´Ï´Ù.

°¡°ø ¹× Á¤Á¦ÀÇ ¹ßÀüÀº Ç÷Àå À¯µµÃ¼ÀÇ Ç°Áú°ú ¿ëµµ¸¦ ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

°¡°ø, ºÐȹ, Á¤Á¦ÀÇ ±â¼ú ¹ßÀüÀ¸·Î ¼Ò Ç÷Àå À¯µµÃ¼ÀÇ Ç°Áú, Àϰü¼º, Àû¿ë ¹üÀ§°¡ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ¸·¿©°ú, Å©·Î¸¶Åä±×·¡ÇÇ ±â¼ú, ºÐ¹«°ÇÁ¶ µî Á¤±³ÇÑ ºÐ¸® ±â¼úÀ» ÅëÇØ ÇöÀç °³º° Ç÷Àå ´Ü¹éÁúÀ» ÃÖ¼ÒÇÑÀÇ º¯¼ºÀ¸·Î Á¤È®ÇÏ°Ô ºÐ¸®ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °³¼±Àº ´õ ³ôÀº »ý¹°ÇÐÀû Ȱ¼º, ´õ ³ªÀº ¿ëÇØµµ, ´õ Ç¥ÁØÈ­µÈ Á¦Á¦¸¦ º¸ÀåÇϸç, ÀÌ´Â ÀǾàǰ ¹× Áø´Ü ¿ëµµ¿¡ ÇʼöÀûÀÔ´Ï´Ù. »ç·á ¿ëµµ¿¡¼­ Àú¿Â ºÐ¹« °ÇÁ¶ ±â¼úÀº ¸é¿ª±Û·ÎºÒ¸°°ú ÆéƼµåÀÇ »ý¹°ÇÐÀû Ȱ¼ºÀ» À¯ÁöÇÏ¿© ÃÖÁ¾ Á¦Ç°ÀÌ µ¿¹°ÀÇ ¸é¿ª ¹ÝÀÀÀ» Á¶ÀýÇϰí Àå °Ç°­À» ÃËÁøÇÏ´Â µ¥ ´õ È¿°úÀûÀÔ´Ï´Ù. ´Ü¹éÁúüÇÐ ºÐ¼®°ú ¹ÙÀÌ¿À ºÐ¼®Àº Ç÷Àå À¯·¡ ´Ü¹éÁúÇÁ·ÎÆÄÀϸµ ¹× Ư¼º ºÐ¼®¿¡ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖÀ¸¸ç, ƯÁ¤ ±â´É¼ºÀ» °¡Áø Ç¥Àû Á¦Á¦ °³¹ßÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ·¯½º ºñȰ¼ºÈ­ ´Ü°è¿Í ¹èÄ¡ ÃßÀû¼ºÀ» Æ÷ÇÔÇÑ ¾ö°ÝÇÑ Ç°Áú º¸Áõ ÇÁ·ÎÅäÄÝÀ» ÅëÇØ À̵é À¯µµÃ¼ÀÇ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀº Àΰ£°ú µ¿¹°¿ë ¿ëµµ ¸ðµÎ¿¡¼­ °­È­µÇ¾ú½À´Ï´Ù. »ý¸í°øÇÐ ±â¾÷µµ ¼Ò Ç÷Àå ¼ººÐÀÇ ±â´ÉÀû Ư¼ºÀ» ¸ð¹æÇϰųª °­È­ÇÏ´Â ÀçÁ¶ÇÕ ±â¼úÀ» ¿¬±¸ÇÏ¿© Ä¡·á °¡´É¼ºÀ» ´õ¿í ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ÀÎĸ½¶·¹ÀÌ¼Ç ¹× ³ª³ë Á¦ÇüÈ­ ±â¼ú Çõ½ÅÀº ¾à¹°Àü´Þ ¿ëµµ¿¡ »õ·Î¿î ¹®À» ¿­°í ÀÖÀ¸¸ç, ¼ÒÀÇ ¾ËºÎ¹Î°ú ±Û·ÎºÒ¸°Àº ÀǾàǰ Ȱ¼º ¼ººÐÀÇ ¿î¹Ýü·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº ´Ù¾çÇÑ ½ÃÀå¿¡¼­ Àϰü¼º, ¾ÈÀü¼º, À¯È¿¼ºÀ» º¸ÀåÇÔÀ¸·Î½á ±ÔÁ¦ ´ç±¹ÀÇ ¼ö¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ¼Ò Ç÷Àå À¯µµÃ¼´Â ±âº»ÀûÀÎ ±â´É¼º ¼ÒÀç¿¡¼­ ÃÖ÷´Ü Ä¡·á ¹× ¿µ¾ç ¼Ö·ç¼Ç¿¡ »ç¿ëµÇ´Â °íµµ·Î Á¤Á¦µÈ ¹ÙÀÌ¿À ±â´É¼º ¼ÒÀç·Î ÀüȯµÇ°í ÀÖ½À´Ï´Ù.

¼¼°è ¼Ò Ç÷Àå À¯µµÃ¼ ¼ö¿ä¸¦ Çü¼ºÇÏ´Â Áö¿ª ¹× »ê¾÷º° ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼Ò Ç÷Àå À¯µµÃ¼¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä´Â Áö¿ªº° ±ÔÁ¦, »ê¾÷ ¿ªÇÐ, ºÎ¹®º° ¿ì¼±¼øÀ§¿¡ µû¶ó Å©°Ô ¿µÇâÀ» ¹Þ½À´Ï´Ù. ºÏ¹Ì¿Í ¼­À¯·´¿¡¼­´Â Ȱ¹ßÇÑ »ý¹° ÀÇÇÐ ¿¬±¸, ÷´Ü ÀǾàǰ Á¦Á¶, °íµµ·Î ¹ß´ÞÇÑ Ãà»ê¾÷ÀÌ °í¼øµµ Ç÷Àå ´Ü¹éÁú¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ À̵é Áö¿ª¿¡¼­´Â µ¿¹°¼º ¿ø·á¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ À¯ÁöµÇ°í ÀÖÀ¸¸ç, Á¦Á¶¾÷ü°¡ ÃßÀû °¡´ÉÇÑ Á¶´Þ ¹× È¿°úÀûÀÎ °¡°ø ±â¼ú¿¡ ÅõÀÚÇϵµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â µ¿¹° ¿µ¾çÇп¡ ´ëÇÑ ÅõÀÚ Áõ°¡, °íÈ¿À² »ç·á ¿ø·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Áß±¹, Àεµ, Çѱ¹ µîÀÇ ±¹°¡¿¡¼­ ¹ÙÀÌ¿ÀÀǾàǰ »ý»ê ´É·ÂÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀ¸·Î ÀÎÇØ ½ÃÀåÀÌ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«, ƯÈ÷ ºê¶óÁú°ú ¾Æ¸£ÇîÆ¼³ª´Â ¼Ò »çÀ°µÎ¼ö°¡ ¸¹°í ¼öÃâ ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖÀ¸¸ç, ¼Ò ¿øÇ÷ÀÇ ÁÖ¿ä °ø±Þ±¹À¸·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ÀÌ Áö¿ªÀ» ¼¼°è °ø±Þ¸ÁÀÇ Áß¿äÇÑ ¿¬°á°í¸®·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÀϺΠÁö¿ª¿¡¼­´Â À°·ù ¼Òºñ Áõ°¡¿Í Çö´ë »ç·á »ê¾÷ÀÇ ¹ßÀüÀ¸·Î Ç÷Àå ±â¹Ý µ¿¹° »ç·á º¸ÃæÁ¦¿¡ ´ëÇÑ »õ·Î¿î ±âȸ°¡ âÃâµÇ°í ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç´Â ÁÖ»çÁ¦ ¹× °æ±¸Á¦ Á¦Á¦¿ëÀ¸·Î °í¼øµµ ¹× º´¿ø±ÕÀÌ ¾ø´Â À¯µµÃ¼¸¦ ¿ä±¸Çϰí, »ç·áȸ»ç´Â °¡ÃàÀÇ Àå³» ¸é¿ª°ú »ç·á È¿À²À» Çâ»ó½ÃŰ´Â »ý¸®È°¼º ´Ü¹éÁú ºí·»µå¸¦ ¿ì¼±½ÃÇÕ´Ï´Ù. ±â´É¼º ½Äǰ°ú °Ç°­±â´É½Äǰ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¿¬±¸ÀÚµéÀº Ç÷Àå À¯·¡ ÆéƼµå¸¦ Àΰ£ÀÇ ¿µ¾ç°ú °Ç°­¿¡ Ȱ¿ëÇϱâ À§ÇØ Ç÷Àå À¯·¡ ÆéƼµåÀÇ Àû¿ë ¹üÀ§¸¦ ³ÐÇô°¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ´Ù¸éÀûÀÎ Áö¿ªÀû, ºÎ¹®º° ¿ªÇÐÀÌ ´Ù¾çÈ­µÇ¸é¼­µµ »óÈ£ ¿¬°è¼ºÀÌ °­È­µÇ°í ÀÖ´Â ¼Ò Ç÷Àå À¯·¡ Á¦Ç° ¼¼°è ½ÃÀåÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

¼Ò Ç÷Àå À¯µµÃ¼ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

¼Ò Ç÷Àå À¯µµÃ¼ ½ÃÀåÀÇ ¼ºÀåÀº °Ç°­¿¡ ÃÊÁ¡À» ¸ÂÃá Çõ½Å, Áö¼Ó°¡´ÉÇÑ ´Ü¹éÁú °ø±Þ¿ø¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, µ¿¹° ¹× Àΰ£ ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ Àü ¼¼°è ¼ö¿ä Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ µÅÁö¿Í ¼Û¾ÆÁö ¿µ¾ç¿¡¼­ Ç÷Àå ´Ü¹éÁúÀÇ »ç·á ÀÌ¿ëÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, Ãʱ⠸鿪 ¹ß´ÞÀ» Áö¿øÇϰí, Æó»çÀ²À» ³·Ã߸ç, »ç·á Àüȯ È¿À²À» Çâ»ó½ÃŰ´Â °ÍÀÌ Å« ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. Ç×»ýÁ¦ ³»¼º¿¡ ´ëÇÑ ¼¼°èÀûÀÎ Ãß¼¼¿¡ ´ëÇÑ ¿ì·Á ¼Ó¿¡¼­ Ç÷Àå°ú °°Àº ±â´É¼º »ç·á ¿ø·áÀÇ »ç¿ëÀº Ç×»ýÁ¦¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ÀÚ¿¬Àû ´ë¾ÈÀ¸·Î ¿©°ÜÁö°í ÀÖÀ¸¸ç, Áö¼Ó°¡´ÉÇϰí Ã¥ÀÓ°¨ ÀÖ´Â Ãà»êÀ» ÁöÇâÇÏ´Â ¾÷°è µ¿Çâ°úµµ ÀÏÄ¡ÇÕ´Ï´Ù. ¹ÙÀÌ¿À¸ÞµðÄà ºÐ¾ß¿¡¼­´Â ¼¼Æ÷¹è¾ç ¹èÁö, ´Ü¹éÁú ±â¹Ý ¾ÈÁ¤Á¦, Ä¡·á¿ë ºÎÇüÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó °í¼øµµ Ç÷Àå À¯µµÃ¼¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¹é½Å, ¸ð³ëŬ·Î³Î Ç×ü, Àç»ýÄ¡·áÁ¦ µî ¹ÙÀÌ¿ÀÀǾàǰ °³¹ßÀÌ ±ÞÁõÇϸ鼭 ±× ÀûÇÕ¼º°ú ¼º´ÉÀÌ ÀÔÁõµÈ Ç÷Àå À¯·¡ ¼ººÐ¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ µ¿¹°¼º Á¦Ç°º°·Î Ç÷Àå ´Ü¹éÁú°ú °°Àº °íºÎ°¡°¡Ä¡ ¼ÒÀç·Î ÀüȯÇÔÀ¸·Î½á Æó±â¹°À» ÁÙÀ̰í À°·ù »ý»ê ½Ã½ºÅÛ ÀüüÀÇ ÀÚ¿ø È¿À²¼ºÀ» ³ôÀÏ ¼ö ÀÖÀ¸¸ç, Áö¼Ó°¡´É¼º Ãø¸é¿¡¼­µµ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ °¡°ø ±â¼úÀÇ ¹ßÀü°ú ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©ÀÇ °­È­·Î ÀÎÇØ ½ÃÀå Àü¹ÝÀÇ ½Å·Ú¿Í äÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °¡Ãà »ý»ê¼º Çâ»ó, ÇコÄÉ¾î ¿¬±¸, ´Ü¹éÁú ¿£Áö´Ï¾î¸µ¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ½ÃÀå È®´ë¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù. ³ó¾÷, »ý¸í°øÇÐ, Á¦¾àÀÇ À¶ÇÕÀÌ °¡¼ÓÈ­µÊ¿¡ µû¶ó ¼Ò Ç÷Àå À¯µµÃ¼´Â ¿µ¾ç °ÝÂ÷¸¦ ÇØ¼ÒÇϰí, Ä¡·á °á°ú¸¦ °³¼±Çϸç, ¼¼°è °æÁ¦ Àü¹Ý¿¡ ºñ¿ë È¿À²ÀûÀÎ ±â´É¼º ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

À¯µµÃ¼(¸é¿ª±Û·ÎºÒ¸° À¯µµÃ¼, ÇǺ긮³ë°Õ À¯µµÃ¼, ¼Ò Ç÷û¾ËºÎ¹Î À¯µµÃ¼, ¼Ò ÅÂ¾Æ Ç÷û À¯µµÃ¼, ½Å»ý ¼Û¾ÆÁö Ç÷û À¯µµÃ¼, Æ®·Òºó À¯µµÃ¼, ±âŸ À¯µµÃ¼), ÃÖÁ¾»ç¿ëÀÚ(»ê¾÷ ÃÖÁ¾»ç¿ëÀÚ, Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ÃÖÁ¾»ç¿ëÀÚ, Çмú¡¤¿¬±¸±â°ü ÃÖÁ¾»ç¿ëÀÚ, ½Äǰ ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Bovine Blood Plasma Derivatives Market to Reach US$2.4 Billion by 2030

The global market for Bovine Blood Plasma Derivatives estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Immunoglobulin Derivative, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$671.7 Million by the end of the analysis period. Growth in the Fibrinogen Derivative segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$515.1 Million While China is Forecast to Grow at 7.1% CAGR

The Bovine Blood Plasma Derivatives market in the U.S. is estimated at US$515.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$479.2 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Bovine Blood Plasma Derivatives Market - Key Trends & Drivers Summarized

Why Are Bovine Blood Plasma Derivatives Critical to the Biomedical and Animal Nutrition Industries?

Bovine blood plasma derivatives have emerged as vital components across several sectors, particularly in biomedical research, pharmaceutical manufacturing, and animal nutrition. These derivatives, obtained from the plasma fraction of bovine blood, are rich in functional proteins such as albumin, immunoglobulins, fibrinogen, and growth factors. In the biomedical field, they are widely used as culture media supplements, stabilizing agents for vaccines, and carriers for drug formulations. Their compatibility with human and animal cell systems makes them ideal for tissue engineering, diagnostics, and the development of biopharmaceuticals. In the animal nutrition industry, bovine plasma proteins serve as high-quality feed additives, especially in piglet and calf diets, promoting immune support and improving gut health during early growth stages. The use of bovine blood plasma in feed not only enhances growth performance but also reduces the need for antibiotics, aligning with the global movement toward antibiotic-free animal husbandry. Furthermore, these derivatives are processed under stringent safety protocols, ensuring low pathogen risk and consistent bioactivity. The demand for functional proteins from sustainable sources is steadily increasing, and bovine blood plasma derivatives provide a cost-effective solution that makes use of what would otherwise be a by-product of meat processing. This makes them environmentally beneficial while delivering high value to multiple end-use industries. As global populations grow and the demand for both biomedical products and animal protein rises, bovine blood plasma derivatives continue to play a crucial and expanding role in enhancing health outcomes and nutritional performance across sectors.

How Are Advances in Processing and Purification Elevating the Quality and Applications of Plasma Derivatives?

Technological advancements in processing, fractionation, and purification are greatly enhancing the quality, consistency, and scope of applications for bovine blood plasma derivatives. Sophisticated separation technologies, including membrane filtration, chromatographic techniques, and spray drying, now allow for precise isolation of individual plasma proteins with minimal denaturation. These improvements ensure higher biological activity, better solubility, and more standardized formulations, which are essential for pharmaceutical and diagnostic use. In feed applications, low-temperature spray drying techniques preserve the bioactivity of immunoglobulins and peptides, making the final product more effective in modulating the immune response and promoting gut health in animals. Proteomic analysis and bioassays are increasingly used to profile and characterize plasma-derived proteins, enabling the development of targeted formulations with specific functionalities. Additionally, stringent quality assurance protocols, including viral inactivation steps and batch traceability, have strengthened the safety profile of these derivatives for both human and veterinary applications. Biotech companies are also exploring recombinant technologies to mimic or enhance the functional properties of bovine plasma components, further expanding their therapeutic potential. Innovations in encapsulation and nano-formulation are opening new doors for drug delivery applications, where bovine albumin and globulins are used as carriers for active pharmaceutical ingredients. These technological strides are also supporting regulatory acceptance by ensuring consistency, safety, and efficacy across different markets. As a result, bovine blood plasma derivatives are transitioning from basic functional ingredients to highly refined bio-functional materials used in cutting-edge therapeutic and nutritional solutions.

What Regional and Industry-Specific Factors Are Shaping the Demand for Bovine Plasma Derivatives Worldwide?

The global demand for bovine blood plasma derivatives is highly influenced by regional regulations, industry dynamics, and sector-specific priorities. In North America and Western Europe, robust biomedical research, advanced pharmaceutical manufacturing, and highly developed livestock industries drive consistent demand for high-purity plasma proteins. These regions also maintain strict regulatory frameworks around animal-derived materials, encouraging manufacturers to invest in traceable sourcing and validated processing techniques. In Asia-Pacific, the market is expanding rapidly due to growing investments in animal nutrition, increased demand for high-efficiency feed ingredients, and the rapid development of biopharmaceutical capabilities in countries like China, India, and South Korea. Latin America, particularly Brazil and Argentina, is emerging as a major supplier of raw bovine blood due to its large cattle population and growing export infrastructure, positioning the region as a critical link in the global supply chain. In the Middle East and parts of Africa, rising meat consumption and the development of modern feed industries are also creating new opportunities for plasma-based animal feed supplements. Sector-specific trends further influence usage, with pharmaceutical firms demanding highly purified, pathogen-free derivatives for injectable and oral drug formulations, while feed companies prioritize bioactive protein blends that enhance gut immunity and feed efficiency in livestock. The growing interest in functional foods and nutraceuticals is also pushing the boundaries of application, with researchers exploring the use of plasma-derived peptides for human nutrition and wellness. These multifaceted regional and sectoral dynamics are contributing to a diversified yet increasingly interconnected global market for bovine plasma derivatives.

What Are the Primary Drivers Fueling the Growth of the Bovine Blood Plasma Derivatives Market?

The growth in the bovine blood plasma derivatives market is driven by a convergence of health-focused innovations, increasing demand for sustainable protein sources, and the rising global need for both animal and human healthcare solutions. A significant driver is the expanding use of plasma proteins in animal feed, especially in swine and calf nutrition, where they support early immune development, reduce mortality rates, and improve feed conversion efficiency. With global concerns over antibiotic resistance, the use of functional feed ingredients like plasma is seen as a natural alternative to antibiotics, aligning with industry trends toward sustainable and responsible animal agriculture. In the biomedical field, growing demand for cell culture media, protein-based stabilizers, and therapeutic excipients is accelerating the need for high-purity plasma derivatives. The surge in biopharmaceutical development, particularly for vaccines, monoclonal antibodies, and regenerative therapies, has intensified reliance on plasma-based components due to their proven compatibility and performance. Sustainability also plays a pivotal role, as the valorization of animal by-products into high-value materials like plasma proteins reduces waste and enhances overall resource efficiency within the meat production system. Additionally, advancements in processing and a stronger regulatory framework have increased trust and adoption across markets. Increased investments in livestock productivity, healthcare research, and protein engineering further contribute to market expansion. As the convergence of agriculture, biotechnology, and pharmaceuticals continues to accelerate, bovine blood plasma derivatives are expected to remain essential in bridging nutritional gaps, improving therapeutic outcomes, and delivering cost-effective, functional solutions across the global economy.

SCOPE OF STUDY:

The report analyzes the Bovine Blood Plasma Derivatives market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Derivative (Immunoglobulin Derivative, Fibrinogen Derivative, Bovin Serum Albumin Derivative, Fetal Bovin Serum Derivative, Newborn Calf Serum Derivative, Thrombin Derivative, Other Derivatives); End-User (Industrial End-User, Pharma & Biotech Companies End-User, Academic & Research Institutes End-User, Food End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â